AI Article Synopsis
- The study investigates the outcomes and safety of high-dose-rate image-guided adaptive brachytherapy followed by minimally invasive surgery for early-stage cervical cancer.
- The research analyzed data from 70 patients, revealing a 98% rate of local relapse-free survival and a 97% overall survival rate after three years, with minimal complications reported.
- The findings suggest that this treatment approach effectively controls cancer while reducing the need for additional therapies, highlighting its potential benefits in managing early-stage cervical cancer.
Article Abstract
Purpose: To analyze the clinical outcomes and the safety of preoperative high-dose-rate (HDR) image-guided adaptive brachytherapy (IGABT) followed by minimally invasive surgery (MIS) in the multidisciplinary management of early-stage cervical cancer.
Methods And Materials: Medical records of all consecutive patients with early-stage cervical cancer treated at our institution between 2012 and 2018 with preoperative IGABT in a multidisciplinary approach were reviewed. Treatment schedule was pelvic node dissection, preoperative IGABT followed 6-8 week later by MIS hysterectomy.
Results: Seventy patients with cervical cancer FIGO stages (IB1 18.6%, IB2 75.7% and IIA1 5.7%) were treated by preoperative HDR brachytherapy. With a median follow-up of 37.4 months [95% confidence interval, 32.1-39.7 months] isolated vaginal vault recurrence was not observed, 3 pelvic relapses were reported (4.3%). None of patients received postoperative radiotherapy (EBRT) or radiochemotherapy. The estimated 3-year local and pelvis relapse free survival for the entire population were respectively 98% [95% confidence interval, 89%-100%] and 90% [80%-96%]. The estimated 3-year disease-free survival (DFS) for the entire population was 88% [77-94%]. The 3-year overall survival (OS) rate was 97% [88%-99%]. Microscopic vaginal resection margin (R1) was observed in one patient ([1].4%). Lymph-vascular space invasion (LVSI) was found found in 6 (8.6%) patients. Forty-eight late complications in 36 patients (51.4%) were observed. Five (7.1%) grade 3 vaginal wound dehiscence toxicities were observed. Urinary and gastrointestinal toxicities were grade 1-2. No grade 4-5 complications were observed.
Conclusions: Preoperative image-guided adaptive brachytherapy followed by minimally invasive surgery allows high local control, reduces positive surgical margins and rates of lymph-vascular space invasion avoiding adjuvants treatments. Surgical approaches must be discussed with patients including preoperative brachytherapy as a down-staging treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ygyno.2021.01.034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mesonephric and Mesonephric-like Adenocarcinomas of the Gynecologic Tract: A Case Series and a Review of the Literature.
Int J Gynecol Pathol
January 2025
Department of Obstetrics & Gynecology, Division of Gynecologic Oncology.
We sought to present and describe all cases of mesonephric adenocarcinoma (MNAC) and mesonephric-like adenocarcinomas (MLAs) at our institution. These cancers are rare, morphologically similar tumors of the female reproductive tract. In this case series, we present 13 new cases of MNAC/MLA that were identified at St.
View Article and Find Full Text PDFDetection of alteration in carotid artery volumetry using standard-of-care computed tomography surveillance scans following unilateral radiation therapy for early-stage tonsillar squamous cell carcinoma survivors: a cross-sectional internally-matched carotid isodose analysis.
Clin Transl Radiat Oncol
March 2025
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Aim: This study leveraged standard-of-care CT scans of patients receiving unilateral radiotherapy (RT) for early tonsillar cancer to detect volumetric changes in the carotid arteries, and determine whether there is a dose-response relationship.
Methods: Disease-free cancer survivors (>3 months since therapy and age > 18 years) treated with intensity modulated RT for early (T1-2, N0-2b) tonsillar cancer with pre- and post-therapy contrast-enhanced CT scans available were included. Patients treated with definitive surgery, bilateral RT, or additional RT before the post-RT CT scan were excluded.
An automatic cervical cell classification model based on improved DenseNet121.
Sci Rep
January 2025
Department of Biomedical Engineering, School of Life Science and Technology, Changchun University of Science and Technology, Changchun, 130022, China.
The cervical cell classification technique can determine the degree of cellular abnormality and pathological condition, which can help doctors to detect the risk of cervical cancer at an early stage and improve the cure and survival rates of cervical cancer patients. Addressing the issue of low accuracy in cervical cell classification, a deep convolutional neural network A2SDNet121 is proposed. A2SDNet121 takes DenseNet121 as the backbone network.
View Article and Find Full Text PDFAberrant promoter methylation of CTHRC1 gene and its clinicopathological characteristics in head and neck cancer.
Int J Oral Maxillofac Surg
January 2025
Molecular Biology Laboratory, Centre for Cellular and Molecular Research, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, India. Electronic address:
Head and neck squamous cell carcinoma (HNSCC) is genetically complex and difficult to treat. Detection in the early stage is challenging, leading to diagnosis at advanced stages with limited treatment options. This study examined the collagen triple helix repeat containing 1 gene (CTHRC1) as a potential biomarker and therapeutic target in HNSCC.
View Article and Find Full Text PDFA Canadian Perspective on Systemic Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma.
Curr Oncol
January 2025
Department of Medical Oncology, Arthur JE Child Comprehensive Centre, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 5G2, Canada.
Although the majority of patients with nasopharyngeal carcinoma (NPC) present with early-stage or locoregional disease that can be treated with definitive radiotherapy, approximately 20% of patients experience disease recurrence, and 15% present with metastatic disease that is not amenable to curative therapy. Management of patients with recurrent or metastatic (r/m) NPC who are not candidates for local salvage therapy is challenging in Canada, as there is uncertainty in extrapolating evidence that is largely generated from Southeast China to non-endemic regions such as Canada. Currently, treatment options in Canada are limited to chemotherapy regimens that can only achieve short-term response and prolongation of survival.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!